Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Omaha, Nebraska 68198


RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Radiolabeled monoclonal antibodies can locate and deliver radioactive cancer-killing substances. PURPOSE: Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibodies with rituximab in treating patients who have non-Hodgkin's lymphoma that has not responded to high-dose chemotherapy and autologous stem cell transplantation.

Study summary:

OBJECTIVES: - Determine the maximum tolerated dose of yttrium Y 90-labeled ibritumomab tiuxetan when administered with rituximab in patients with B-cell non-Hodgkin's lymphoma who have relapsed after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. - Determine the safety and efficacy of this regimen in these patients. OUTLINE: This is a dose-escalation study of yttrium Y 90-labeled ibritumomab tiuxetan (IDEC-Y2B8). - Phase I: Patients receive rituximab IV over 4-6 hours followed by indium In 111-labeled ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0. Patients receive rituximab IV again on day 7 followed by IDEC-Y2B8 IV over 10 minutes. Cohorts of 3-6 patients receive escalating doses of IDEC-Y2B8 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 3 of 6 patients experience dose-limiting toxicity. - Phase II: Once the MTD is determined, 58 additional patients are treated at that dose level as in phase I. Patients are followed at 6 weeks, every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: Approximately 78 patients (20 for phase I and 58 for phase II) will be accrued for this study within 2 years.


DISEASE CHARACTERISTICS: - Diagnosis of relapsed B-cell non-Hodgkin's lymphoma (NHL) after high-dose chemotherapy and autologous stem cell transplantation - Less than 25% bone marrow involvement with NHL as evidenced by unilateral or bilateral biopsy within the past 6 weeks - Bone marrow biopsy should demonstrate 15-20% of cellular space occupied by normal hematopoiesis - CD20 antigen expression in tumor tissue within the past year as evidenced by 1 of the following: - Immunoperoxidase stains of tissue showing positive reactivity with L26 antibody - Flow cytometry studies - Measurable disease - More than 2 cm bidimensionally - No active CNS lymphoma - No HIV- or AIDS-related lymphoma PATIENT CHARACTERISTICS: Age: - 19 and over Performance status: - WHO 0-2 Life expectancy: - At least 3 months Hematopoietic: - Absolute neutrophil count greater than 1,500/mm^3 - Platelet count greater than 150,000/mm^3 - No transfusion dependency Hepatic: - Bilirubin less than 2.0 mg/dL - SGOT or SGPT no greater than 2.5 times upper limit of normal (unless due to lymphomatous infiltration of the liver) Renal: - Creatinine less than 2.0 mg/dL - No active obstructive hydronephrosis Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after study therapy - HIV negative - No active infection requiring oral or IV antibiotics - No human antimurine antibody positivity - No other major medical problems PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics - At least 4 weeks since prior growth factors - At least 4 weeks since prior biologic therapy - No dependency on hematopoietic growth factors (e.g., epoetin alfa, interleukin-11, filgrastim [G-CSF], or sargramostim [GM-CSF]) - No prior radioimmunotherapy - No other concurrent biologic therapy of any kind Chemotherapy: - See Disease Characteristics - At least 4 weeks since any prior cytotoxic chemotherapy (6 weeks for nitrosoureas) - No prior fludarabine - No concurrent chemotherapy Endocrine therapy: - No concurrent steroids except as maintenance for non-cancerous disease Radiotherapy: - See Biologic therapy - At least 4 weeks since prior radiotherapy - No prior pelvic radiotherapy - No prior radiotherapy to more than 25% of estimated bone marrow reserve - No concurrent external beam radiotherapy Surgery: - Not specified Other: - Recovered from all prior therapy - At least 4 weeks since prior immunosuppressants - No other concurrent investigational drugs - No other concurrent anti-cancer therapy



Primary Contact:

Study Chair
Julie M. Vose, MD
University of Nebraska

Backup Contact:


Location Contact:

Omaha, Nebraska 68198
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.